Leerink Trims Valuation Range on Questcor (QCOR); Still Sees Broader Acthar Risk
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Ladenburg Thalmann Upgrades Questcor Pharmaceuticals (QCOR) to Buy
October 24, 2012 9:16 AM EDTLadenburg Thalmann upgraded Questcor Pharmaceuticals (NASDAQ: QCOR) from Neutral to Buy following Q3 results.
For an analyst ratings summary and ratings history on Questcor Pharmaceuticals click here. For more ratings news on Questcor Pharmaceuticals click here.
Shares of Questcor Pharmaceuticals closed at $25.93 yesterday, with a 52 week range of $17.25-$58.91.... More
Questcor Pharmacueticals (QCOR) Tops Q3 EPS by 20c
October 23, 2012 4:03 PM EDTQuestcor Pharmacueticals (NASDAQ: QCOR) reported Q3 EPS of $0.97, $0.20 better than the analyst estimate of $0.77. Revenue for the quarter came in at $140.3 million versus the consensus estimate of $128.97 million.
For earnings history and earnings-related data on Questcor Pharmacueticals (QCOR) click here.... More
